Contracted ELISPOT Testing for Immune Monitoring

CTL has years of experience in contracted research. Many pharmaceutical and biotechnology companies have entrusted CTL with evaluating cell-mediated immunity (CMI) to their vaccines, drugs, and biologic products using the enzyme-linked immunospot (ELISPOT) technique.

Are you using the appropriate readout system for evaluating your test subject response? CTL’s greatest strength lies in its high-throughput T-cell monitoring capabilities and world-class ELISPOT expertise.

The ELISPOT technique allows researchers to generate secretory footprints in the form of coloured spots within a 96-well plate. These images are then scanned, counted, and readily evaluated for statistical significance. The ELISPOT method can be used to determine whether a patient population responds positively or negatively to a vaccine, drug or biologic product, as well as measure the extent of each person’s immune response.

This method opens the door for a variety of tests, such as:

• Testing T-cell mediated immunity at a single-cell level for pre-clinical and clinical specimens
• Antigen determinant mapping with overlapping peptides
• Measurement of cytotoxic T-cell responses
• Measurement of B-cell responses
• The ability to run multiple assays using a limited num­ber of cells (such as perform two sequential ELISPOT assays using the same cells or perform an ELISPOT assay, harvest cells and use them in flow cytometry)

The ability to measure cell-mediated immunity to antigens using ELISPOT is vital when measurement of the ex-vivo, low-frequency T-cell responses is required. The T-cell readout at a single-cell resolution using the ELISPOT technique is necessary to achieve this goal.

CTL has developed, optimised, qualified and validated test methods for its clients in various test systems, including human, monkey, mouse, rat, rabbit, and pig. This has provided CTL a wealth of expertise encompassing a wide range of assay types, ranging from ELISPOT to enzyme-linked immunosorbent assay (ELISA), multiplex bead arrays, and fluorescence-activated cell sorting (FACS) in a non-regulated and regulated environment.

CTL has a good laboratory practice (GLP) compliant, high-throughput laboratory capable of processing 150 samples per day and up to 450 samples per week. This allows the company to significantly speed up the development process for vaccines entering the clinical testing phase and their subsequent immune monitoring.

CTL’s team of highly-trained scientists will gladly assist in all phases of your study.